You are here

endometriosis

Organon finally offers a larger pharma model for women's health. But 'one company can't do it by itself'

Organon finally offers a larger pharma model for women's health. But 'one company can't do it by itself'

Fierce Biotech

Flag link:

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

Endpoints

Teva Pharmaceuticals

Flag link:

Pfizer and Myovant’s endometriosis pain drug Myfembree gets another FDA nod

Pfizer and Myovant’s endometriosis pain drug Myfembree gets another FDA nod

Endpoints

Flag link:

Myovant and Pfizer’s path to securing a second nod for Myfembree gets hazy — and investors react quickly

Myovant and Pfizer’s path to securing a second nod for Myfembree gets hazy — and investors react quickly

Endpoints

Flag link:

Organon makes another women’s health move with deal for endometriosis-focused Forendo

Organon makes another women’s health move with deal for endometriosis-focused Forendo

MedCity News

Flag link:

Myovant Squares Off with AbbVie On Endometriosis Treatment

Myovant Squares Off with AbbVie On Endometriosis Treatment

Motley Fool

Myovant Sciences

clinical trials

Flag link:

AbbVie's new endometriosis drug to cost $10K per year

AbbVie's new endometriosis drug to cost $10K per year

Biopharma Dive

Flag link:

AbbVie wins FDA approval for oral treatment for endometriosis pain

AbbVie wins FDA approval for oral treatment for endometriosis pain

Marketwatch

Flag link:

3 Biotech Stocks With Major Potential Catalysts in July

3 Biotech Stocks With Major Potential Catalysts in July

Yahoo/Motley Fool

Neurocrine Biosciences

INSYS Therapeutics

Flag link:

AbbVie's elagolix could put pressure on budgets, ICER estimates

AbbVie's elagolix could put pressure on budgets, ICER estimates

Biopharma Dive

Flag link:

Elagolix review extended

Flag link:

FDA Requires More Time to Review Abbvie and Neurocrine Endometriosis Drug Elagolix

FDA Requires More Time to Review Abbvie and Neurocrine Endometriosis Drug Elagolix

CP Wire

Flag link:

New Study Reveals Potential for DotLab Endometriosis Saliva Test to be Used for Monitoring Disease Progression and Treatment Response

New Study Reveals Potential for DotLab Endometriosis Saliva Test to be Used for Monitoring Disease Progression and Treatment Response

CP Wire

Flag link:

Lumenis reports exciting study outcomes for its endometriosis treatment

Lumenis reports exciting study outcomes for its endometriosis treatment

CP Wire

Flag link:

Lumenis reports exciting study outcomes for its endometriosis treatment

Flag link:

AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII

AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII

Endpoints

uterine fibroids

Flag link:

Enteris endometriosis drug moves ahead with proof-of-concept

Enteris endometriosis drug moves ahead with proof-of-concept

Biopharma Dive

Enteris BioPharma

Flag link:

This drug may be able to treat both women’s health disorders and prostate cancer

This drug may be able to treat both women’s health disorders and prostate cancer

Marketwatch

prostate cancer

uterine fibroids

Flag link:

Enteris BioPharma launches endometriosis trial with oral peptide delivery tech

Enteris BioPharma launches endometriosis trial with oral peptide delivery tech

Drug Delivery Business News

Enteris BioPharma

Flag link:

AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix

AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix

Endpoints

clinical trials

Flag link:

Pages